WeVote
Log In

Bill

Bill

HB 1062

Providing coverage for biomarker testing.

2025-2026 Regular Session Introduced by Emily Alvarado and 19 co-sponsors

HB 1062 mandates Washington health insurers cover biomarker testing to improve disease detection and personalized treatment access while potentially raising insurance costs.

Public hearing in the House Committee on Health Care & Wellness at 1:30 PM.
0
WeVote Research Nonpartisan
Bill Summary · HB 1062

Legislative bill overview

HB 1062 would require health insurance coverage for biomarker testing in Washington State. Biomarker tests identify biological markers that can indicate disease risk, progression, or treatment response. The bill aims to ensure patients have access to these diagnostic tools without prohibitive out-of-pocket costs.

Why is this important

Biomarker testing can enable earlier disease detection and personalized treatment decisions, potentially improving health outcomes and reducing long-term medical costs. However, these tests are often expensive and not universally covered by insurance, creating barriers for patients who could benefit from them. This policy directly affects healthcare affordability and access to precision medicine in Washington.

Potential points of contention

  • Cost and insurance premiums: Expanded coverage mandates typically increase insurance costs, which may be passed to employers and consumers through higher premiums
  • Scope ambiguity: The bill's specific definition of which biomarker tests qualify for coverage is critical; unclear language could lead to disputes over what insurers must cover
  • Medical necessity standards: Disagreement between insurers, providers, and patient advocates over which biomarkers have sufficient clinical evidence to warrant mandatory coverage

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.